The COVID-19 coronavirus epidemic that originated in Wuhan, the capital of China’s Hubei province, has wide-ranging implications for the pharmaceutical industry and healthcare sector alike.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
